ObjectiveTo study the HIVbased lentiviral vector, pLenti6/V5SK, which contains the gene of interest , CXCintrakine (SDFKDEL), on the gene therapy of HIV1 infection. MethodsA pLentibased expression vector, pLenti6/V5DTOPO, was used to produce the lentiviral vector, which was cotransfected with the ViraPowerTM Packaging Mix (pLP1, pLP2, and pLP/VSVG) into 293FT cells to produce a replicationincompetent lentivius stock. After lentiviral stock had been titrated the by  HeLa cells, the expression of the  interest gene of  of SDF1  could be assayed by  indirect immunofluorescence in transduced HeLa cells.ResultsThe lentiviral expression vector, pLenti6/V5SK, was confirmed by restriction enzyme digestion and sequencing. The lentivirus stock was constructed in 293 FT cell line. The fluorescent protein was mainly scattered in cytoplasm and perinucleus in transduced HeLa cells. ConclusionThese findings demonstrated the ability of the lentiviral vector to transduce multiple genes into HeLa cells, and the potential therapeutic effect on the treatment of HIV1 infection.